Stempoint Capital LP Purchases New Shares in BioAge Labs, Inc. $BIOA

Stempoint Capital LP purchased a new position in BioAge Labs, Inc. (NASDAQ:BIOA) in the 1st quarter, HoldingsChannel.com reports. The fund purchased 338,654 shares of the company’s stock, valued at approximately $5,923,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Russell Investments Group Ltd. acquired a new stake in shares of BioAge Labs in the third quarter valued at about $27,000. CWM LLC raised its position in shares of BioAge Labs by 39.9% during the 4th quarter. CWM LLC now owns 3,693 shares of the company’s stock worth $49,000 after purchasing an additional 1,053 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in BioAge Labs by 85.6% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company’s stock valued at $54,000 after buying an additional 5,976 shares in the last quarter. Walleye Capital LLC acquired a new stake in BioAge Labs in the 2nd quarter worth about $64,000. Finally, Bank of America Corp DE boosted its holdings in BioAge Labs by 46.3% in the 3rd quarter. Bank of America Corp DE now owns 11,119 shares of the company’s stock worth $65,000 after buying an additional 3,517 shares during the last quarter.

Analyst Ratings Changes

Several equities research analysts have commented on the company. Wall Street Zen lowered BioAge Labs from a “hold” rating to a “sell” rating in a research note on Sunday, May 17th. Roth Capital initiated coverage on BioAge Labs in a research note on Wednesday, May 27th. They issued a “buy” rating and a $36.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioAge Labs in a research report on Tuesday, July 21st. Finally, BTIG Research started coverage on BioAge Labs in a research note on Wednesday, May 13th. They issued a “buy” rating and a $40.00 price objective for the company. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, BioAge Labs currently has an average rating of “Moderate Buy” and a consensus target price of $43.50.

BioAge Labs Trading Up 1.2%

BIOA opened at $22.19 on Thursday. BioAge Labs, Inc. has a twelve month low of $4.11 and a twelve month high of $25.95. The firm has a market capitalization of $986.41 million, a PE ratio of -9.25 and a beta of 0.61. The firm’s 50-day moving average price is $20.60 and its 200 day moving average price is $19.51.

BioAge Labs (NASDAQ:BIOA) last released its quarterly earnings data on Friday, May 8th. The company reported ($0.52) EPS for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.19. BioAge Labs had a negative net margin of 871.75% and a negative return on equity of 29.40%. The company had revenue of $2.77 million during the quarter. As a group, analysts predict that BioAge Labs, Inc. will post -2.68 earnings per share for the current fiscal year.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.